Dialyzable leukocyte extracts (DLE) transfer specific cell-mediated immune responses from sensitized donors to non-immune recipients. In addition, DLE have several immunomodulatory effects and are used for the treatment of several infectious and non-infectious diseases. Previous studies showed that human DLE obtained from virus-infected leukocytes and bovine DLE decrease the production of the pro-inflammatory cytokine TNF- in response to bacterial lipopolysaccharide, in vitro and in vivo. In the present work, we inquire as to whether DLE from uninfected human leukocytes have the ability to regulate cytokine production in peripheral blood mononuclear cells (PBMC) in vitro. We observed that PBMC from healthy individuals were able to produce TNF-, IL-12 and IL-10 after stimulation with DLE. Moreover, we identified monocytes as the main cell population that produced TNF- after DLE stimulation. Interestingly, we found that DLE contain unidentified ligands that activate Toll-like receptor (TLR)-2. Finally, we observed that DLE directly activated monocytes through TLR-2. These results reveal a new biological activity of DLE, and suggest that part of the immunomodulatory properties of DLE could be attributed to TLR-2 activation on monocytes and to the induction of a pro-inflammatory environment that is crucial for control of infectious diseases.
In 1942, Landsteiner and Chase demonstrated for the first time that isolated leukocytes from immune animals can transfer specific cellmediated immunity to non-immune recipients [1a] . Lawrence demonstrated that cell-mediated immunity can also be transferred by disrupted leukocytes, and by dialyzable leukocyte extracts (DLE) that only contain molecules with a molecular weight below 10 kDa [1b] . The chemical properties and the mechanisms of action of the 'Transfer Factors' (TF) responsible for the transfer of cellmediated immunity [1] are not yet defined, but nevertheless, DLE have many therapeutic and prophylactic applications, especially in diseases where cell-mediated immunity plays a major role. DLE are used for the treatment of herpes virus infection, tuberculosis, mycobacterial diseases, candidiasis, leishmaniasis and other infectious diseases [2] .
In addition to the specific transfer of cell-mediated immunity, DLE have several immunomodulatory effects: they modulate neutrophil chemotaxis, NK cell cytotoxicity and hematopoiesis [3] . DLE also modulate cytokine production. Ojeda et al showed that human DLE obtained from virus-infected leukocytes decrease the production of the pro-inflammatory cytokine TNF- in response to bacterial lipopolysaccharide (LPS) by human monocytes. Bovine DLE also decreased TNF- production in mice treated with LPS [4].
We tested whether human DLE obtained from uninfected leukocytes modulate cytokine production in peripheral blood mononuclear cells (PBMC) and whether a family of innate immune receptors (Toll-Like Receptors, TLR) was involved in this phenomenon. We observed that PBMC from healthy individuals produced the pro-inflammatory cytokines TNF- and IL-12 p40, and the anti-inflammatory cytokine IL-10, 12-72 h after stimulation with DLE ( Figure 1A -D).
Figure 1:
PBMC from healthy individuals produce TNF-, IL-12 p40 (B) and IL-10 (C) after stimulation with DLE. PBMC from healthy individuals were left either unstimulated (NEG) or stimulated with either 250 g/mL DLE or 20 ng/mL LPS. Cell supernatants were collected at the indicated times, and cytokine production was evaluated by enzyme-linked immunosorbent assays (ELISA). Data are expressed as mean ± SD. A representative experiment of three is shown. D) PBMC from 10 healthy donors were either left unstimulated (NEG) or were stimulated with 250 g/mL DLE or 20 ng/mL LPS. All individual results are plotted. *p<0.05, **p<0.01, compared with unstimulated cells.
PBMC contain several cell populations that can produce TNF- including cytotoxic T cells, helper T cells, NK cells, B cells and monocytes.
To discern which cell population was responsible for TNF- induced by DLE, we labeled stimulated PBMC with antibodies against cell surface markers characteristic of the aforementioned cell populations and to intracellular TNF-. In this way, we were able to detect that the only cell population that increased TNF- production after stimulation with DLE was CD14+ monocytes (Figure 2A ). Importantly, this production was Gating strategy for the identification of TNF- production by monocytes. Monocytes were identified by the expression of CD14 and by its size (FSC signal, not shown) and granularity (SSC signal). B) PBMC from 10 healthy donors were either left unstimulated (NEG) or stimulated with 250 g/mL DLE. All individual results are plotted. The values represent the percentage of CD14+ cells (monocytes) that produce TNF- . *p<0.001. observed consistently in 10 healthy donors ( Figure 2B ), which indicates that monocytes are the main producers of TNF- after stimulation with DLE.
Monocytes are critical components of the innate immune response, and have several innate immune receptors that recognize molecules derived from microbes and from damaged tissue. The molecules derived from damaged tissue that activate innate immune receptors are known as Damage Associated Molecular Patterns (DAMP), and we reasoned that DLE could contain this kind of molecule. TLR are a family of innate immune receptors that are activated by microbial molecules and by DAMP, so we investigated if DLE could activate TLR-2 or TLR-4. None of the tested concentrations of DLE stimulated TLR-4-transfected cells ( Figure 3A ), but 10 and 100 g/mL of DLE stimulated TLR-2-transfected cells ( Figure 3B ). These data indicate that DLE contain unidentified ligands (DAMP) that activate TLR-2. To address whether monocytes are directly activated by DLE, purified monocytes from PBMC were stimulated with DLE and TNF- was measured in cell supernatant. Interestingly, purified monocytes were able to produce TNF- after stimulation with DLE; however, PBMC that were depleted of monocytes were unable to produce TNF- after stimulation with DLE ( Figure 4A ).
Finally, like DLE is able to activate TLR-2, we evaluated whether TLR-2 mediates activation of monocytes by DLE. We observed that blocking TLR-2 with a specific monoclonal antibody significantly inhibited TNF- production ( Figure 4B ). These results revealed that DLE directly activates monocytes through TLR-2.
Different reports indicate a therapeutic effect of DLE on several infectious diseases. However, little is known about the mechanisms by which DLE affect the course of an infection. A mechanism traditionally involved is the transfer of cell-mediated immunity by TF present in DLE, which improves cell-mediated response of the receptor and helps to control infection [4] . How cell-mediated response is transferred through TF is not well understood. We propose that an alternative mechanism could be through the activation of innate immune cells, like monocytes, through TLR-2.
Our data suggest the presence of DAMP in DLE, but their identification is still needed. Furthermore, we think that intact DAMP are absent on DLE, because the molecules present have a Mw of less than 12 kDa, and DAMP usually have higher Mw. We suggest that DLE could be present as small DAMP-like defensins, ATP, and adenosine [5] . A second possibility is that DLE contain peptides derived from larger DAMP (such as HSP-72 and HMGB-1) by the enzymatic digestion that occurs during cell lysis, and that these peptides retain the ability to activate TLR-2. It has been reported that fragments of HSP-72 have biological activity, and that peptides derived from HMGB-1 modulate cytokine production and have adjuvant properties [6] .
In conclusion, our results show that DLE are able to activate PBMC to induce the production of TNF-, IL-10 and IL-12. Monocytes were mainly responsible for TNF- production, and DLE presented ligands for TLR-2. Furthermore, DLE directly activated monocytes through TLR-2. These findings support the evidence of DLE as an important regulator of the immune response.
Experimental

Cells and reagents:
Heparinized venous blood was collected from healthy individuals. The Institutional Ethical Committee of ENCB-IPN approved the study, and blood was collected after the donors signed an informed consent. PBMC were isolated as previously described [7] . Briefly, blood from healthy volunteers was diluted 1:2 in sterile PBS and layered on Lymphoprep (Axis-Shield, Oslo, Norway). After centrifugation at 800 x g, mononuclear cells were obtained, and cells were washed 3 times with HBSS. Afterwards, cells were re-suspended in RPMI medium (GIBCO Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco), counted and adjusted to 1X10 6 cells/mL.
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Cells were plated in triplicates in 24-well plates, and were left either unstimulated (negative control), or stimulated with LPS from Escherichia coli (Sigma Chemical Co., St. Louis, MO, USA) or DLE. After incubation for the indicated times at 37 o C in 5% CO 2 , supernatants were collected and cleared by centrifugation at 1,200 x g for 10 min.
DLE was produced by "Proyecto Factor de Transferencia" at ENCB-IPN, as previously described [2b] . Briefly, DLE was prepared from packed blood peripheral leukocytes from healthy donors. Cells were disrupted by 10 cycles of freezing and thawing. The lysate was dialyzed against water using Spectra/Por dialysis membrane with a 'cut-off' of 12kDa (Spectrum Laboratories, CA, USA). Peptide concentration was determined by the bicinchoninic acid method (Pierce Biotechnology, Rockford, IL, USA). DLE was tested free of LPS contamination by the Limulus amebocyte assay (Charles River Laboratories, Charleston, SC, USA).
Cytokine detection by enzyme-linked immunosorbent assay (ELISA):
TNF- (sensitivity ≥7.8 pg/ml), IL-12 p40 (sensitivity ≥31.3 pg/ml) and IL-10 (sensitivity ≥7.8 pg/mL) were quantified in cell culture supernatants according to the manufacturer's protocol (BD Biosciences, San Jose, CA, USA). DLE did not show the presence of any of the cytokines as revealed by ELISA.
Flow cytometry: PBMC were stimulated for 6 h with DLE, with the addition of Brefeldin A (eBioscience, San Diego, CA, USA) for the last 4 h. After incubation, cells were collected, washed and stained with fluorescent-labeled anti-CD3, CD4, CD8, CD14, CD16, CD19, and CD56 (BD Bioscience). Cells were then fixed, permeabilized with BD Cytofix/Cytoperm Kit (BD Bioscience) and stained with anti-TNF- (eBioscience). 1x10 5 total events were acquired in a CyAn flow cytometer (Dako, Denmark) and analyzed with FlowJo software v8.7 (Tree Star Inc., San Carlos, CA, USA).
Detection of TLR ligands in DLE:
To evaluate the presence of TLR ligands in DLE we used the transfection assay of HEK-293 cells, as previously described [8] . Briefly, HEK-293 cells were transiently transfected, using Lipofectamine (Gibco), with expression plasmids for either TLR-2 or TLR-4/MD2 and a luciferase reporter plasmid (InvivoGen, San Diego, CA, USA). Cells were treated with DLE, LPS or Zymosan for 24 h. After incubation, the cells were lysed and the luciferase activity was measured with the Luciferase Assay Reagent (Promega, Madison, WI, USA). Transfected cells showed expression of TLR-2 and TLR-4 as assessed by RT-PCR and flow cytometry.
Blocking of TLR-2 on monocytes: Monocytes were purified from PBMC of healthy volunteers by negative selection with MACS (Miltenyi Biotec, USA). Purity of monocytes was over 90% as assessed by flow cytometry. 2X10 5 monocytes were incubated for 1 h with 10 g/mL of either anti-human TLR-2 (Biolegend, CA, USA) or isotype matched control (Mouse IgG1 , Biolegend, CA, USA). Finally cells were stimulated for 24 h with DLE and TNF- was evaluated in cell supernatant by ELISA.
Data analysis and statistics:
Statistical differences between the control and experimental groups were determined using one-way ANOVA followed by the Newman-Keuls method (GraphPad Prism Software V4, GraphPad, San Diego, CA, USA). Representative experiments are shown; each experiment was repeated independently at least 3 times.
